Articles tagged with Cancer Stem Cells
Scientists at St. Jude Children's Research Hospital have discovered that normal stem cells can give rise to tumors in mature solid tissues, including the intestine. The study identifies Prominin1 as a molecular marker for normal stem cells, which can act as the source of cancerous tumors.
Researchers at the University of Michigan found that a quarter of melanoma cells are 'tumorigenic' and can form new tumors, contradicting previous estimates. The study suggests that targeting these rare cancer stem cells may not be effective in treating melanoma.
A new study reveals that therapy targeting cyclin D1 can block the expansion of breast cancer cells, which are involved in therapy resistance and tumor recurrence. The findings provide a potential new treatment approach for targeted therapies at cancer stem cells in humans.
Researchers identified a molecular mechanism involved in the development of cancer stem cells, which can lead to malignant brain tumors. Targeting this signaling pathway with gene therapy may prevent tumor recurrence.
Scientists have identified distinct gene combinations that define different stem cell types, revealing a single key factor controlling their behavior. This breakthrough has significant implications for manipulating and engineering stem cells to treat human degenerative disorders.
Studies in mice reveal that women who have children young have fewer mammary stem cells, which could contribute to lower breast cancer risk. Researchers plan to investigate further to determine the mechanism behind this protective effect and explore potential treatments.
Researchers have isolated cancer stem cells using a specific protein that only appears in these cells, opening the door for new therapy targeting them. This could lead to a reduction in cancer recurrence by killing stem cells before they can divide.
A new study from the University of Michigan Comprehensive Cancer Center found that HER2-positive breast cancers have four to five times more cancer stem cells than HER2-negative cancers. The drug Herceptin was shown to reduce cancer stem cell numbers by 80 percent, targeting and destroying these cells.
Researchers developed a method to track mesenchymal stem cells in tumors using noninvasive molecular imaging technology. The technique offers promise for personalized medicine and gene-modified stem cell therapies to fight cancer.
Researchers at UCLA identified a type of leukemia stem cell and uncovered the genetic mechanisms that cause normal blood stem cells to become cancerous. This discovery may lead to new therapies targeting these stem cells, potentially curing certain cancers.
Researchers have identified a specific gene expression profile of prostate cancer stem cells, revealing key pathways and potential therapeutic targets. The study's findings offer new hope for treatments targeting the rare but aggressive cancer stem cells.
Researchers have identified an embryonic pathway that confers adult stem cell properties to both normal and cancer cells undergoing epithelial-to-mesenchymal transition, offering a potential route to generate unlimited numbers of stem cells. This discovery has major implications for regenerative medicine and cancer treatment.
A study by researchers at Baylor College of Medicine found that conventional chemotherapy often fails to eliminate breast cancer stem cells, leading to potential relapse. Treatment with lapatinib and other drugs appears to kill both tumor cells and stem cells, reducing the risk of recurrence in patients with HER2-positive tumors.
Researchers have identified and cloned ovarian cancer stem cells, which may be the source of recurrence and resistance to chemotherapy. These stem cells can replicate indefinitely and are highly resistant to conventional treatment.
Recent discoveries suggest that stem cells can serve as potential therapeutic targets for many types of cancers. Researchers have identified specific markers, such as aldehyde dehydrogenase, to isolate cancer-initiating cells and track their response to treatment. These findings hold promise for the development of targeted therapies.
Researchers aim to understand the mechanisms that regulate stem cell function, which may contribute to malignant brain tumor formation. The study finds similarities in stem cell regulation and cancer tumor maintenance, potentially paving the way for targeted therapies.
Researchers found a shared genetic expression pattern between embryonic stem cells and human cancer cells, which may have significant implications for cancer therapeutics. A gene module map was created to relate transcriptional programs in different cell types.
Researchers at Stanford University School of Medicine have successfully created cancer stem cells in a laboratory setting, shedding new light on the origins of these rare and difficult-to-study cells. The breakthrough could lead to new ways of understanding how cancer cells form and developing more effective treatments.
New study finds blood-forming stem cells can survive without Notch signals, allaying fears of damage during chemotherapy. The findings have implications for a high-profile breast-cancer drug trial combining chemotherapy with a Notch inhibitor.
Researchers are exploring stem cell transplants to provide insulin cells for a bioartificial pancreas, addressing the shortage of human pancreatic islet tissue. They also aim to target and destroy cancer stem cells to improve therapies and develop reversible immortalized cell lines.
A new study shows that tumor blood vessels develop from precancerous stem cells, a type of cell that can become malignant. The findings suggest that screening anti-angiogenic drugs should include these cells to improve their effectiveness in blocking tumor growth.
Researchers at Georgetown University Medical Center have discovered both normal and abnormal liver stem cells, which may provide a new target for experimental treatment. The study found that blocking the stat3 gene was effective in preventing liver cancer in mice, opening up new possibilities for treating this devastating disease.
Researchers, led by Dr. Quansheng Du, are studying the complex process of cell division to understand how it can be targeted for cancer therapy. They focus on the mitotic spindle and its role in asymmetric cell division, which may lead to the development of cancer stem cells.
Researchers at Johns Hopkins Kimmel Cancer Center found that cancer stem cells in multiple myeloma share properties with normal stem cells and exhibit resistance to chemotherapy. These cells contain high levels of enzymes that neutralize toxins, making them harder to treat.
The Xie Lab found that Drosophila ovarian germline stem cells can out-compete normal stem cells for a position in the niche by invading neighboring cells and increasing cellular response to E-cadherin. This mechanism ensures only undifferentiated stem cells remain in the niche.
Researchers found that cancer stem cells are stuck at an early developmental stage due to epigenetic repression of BMPR1B, leading to aberrant cell division and tumor growth. Forced expression of silenced BMPR1B restored normal differentiation capacity, offering new therapeutic approaches for glioma patients.
Researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center have identified cancer stem cells as a potential cause of brain tumors. The study aims to develop more accurate and specific cancer diagnoses using these stem cells.
Researchers discovered a genetic switch that regulates critical properties of cancer stem cells using microRNAs. Activating this switch, let-7, can push cancer stem cells to differentiate and lose their tumorigenic abilities, offering a novel approach to targeting these cells with therapeutic RNAs.
Researchers have successfully transferred a new gene to cancer patients via their own stem cells, aiming for stronger treatment with less severe side effects. The study found that six out of eight patients had stem cells carrying the MGMT gene in their blood or bone marrow after treatment.
UMMS associate professor JeanMarie Houghton received a Presidential Early Career Award for Scientists and Engineers, recognizing her work on the link between gastric cancers and bone marrow-derived stem cells. Her research aims to understand the progression of events leading to cancer development and develop targeted treatments.
Researchers at UC Irvine find Imatinib can kill cancerous stem cells, potentially curing CML under certain circumstances. A mathematical formula helps determine the optimal treatment duration.
A new study by UC Irvine scientists suggests that Imatinib can drive cancer into remission in people with chronic myeloid leukemia (CML) if taken over a long enough period of time. The researchers developed a mathematical formula to calculate the optimal treatment duration, which could potentially lead to a cure.
Researchers found that certain cancer treatments can increase the expression of Nanog and BMI1 stem cell markers in cancer cells, allowing them to survive treatment and potentially leading to tumor growth. Understanding these pathways could lead to the development of new therapeutic targets.
Researchers identified a distinct subpopulation of cancer stem cells responsible for metastasis in human pancreatic cancer. The study found that CSCs expressing CD133 and CXCR4 play a critical role in tumor metastasis, and inhibiting these cells or transplanting non-metastatic cells can abolish metastatic tumor development.
The new journal Stem Cell Research will cover all aspects of stem cell research, including embryonic stem cells, cancer stem cells, and developmental studies. It aims to disseminate the results of ongoing research in this rapidly expanding field, with a focus on high-quality peer-reviewed studies.
A Johns Hopkins study shows an experimental compound called cyclopamine successfully kills cancer stem cells that fuel tumor growth and help cancers evade drug and radiation therapy. The study provides evidence for a potential new therapy for glioblastoma, a deadly brain cancer.
Research at the University of Pittsburgh School of Medicine suggests that chemotherapy must target a subset of cancer stem cells to be effective in treating lung cancers. Cancer stem cells, similar to normal stem cells, can resist multiple drug resistance transporters, making them resistant to conventional therapies.
A breast cancer cell line has been found to behave like cancer stem cells, allowing researchers to study the dynamics of cancer stem cells in tissue. This breakthrough could lead to targeted treatments for breast cancer by specifically targeting cancer stem cells for destruction while leaving normal stem cells intact.
Researchers at Stanford University School of Medicine have identified cancer stem cells in colorectal tumors, which can propagate and maintain the growth of the tumor. These stem cells have been found to be responsible for the spread of cancer to distant sites and are likely to be responsible when tumors resurface or spread.
Researchers have identified the cancer stem cell of rhabdomyosarcoma, a childhood cancer, and uncovered a novel genetic signature driving its progression. The discovery opens up new avenues for targeted therapies to prevent recurrence and metastasis.
Researchers found that immune response to SOX2 protein protects against myeloma development in patients with monoclonal gammopathy of undetermined significance. This discovery suggests targeting cancer stem cells may be key to preventing or treating myeloma.
Scientists have discovered a new type of cell that plays a role in cancer development, which can either remain benign or become malignant depending on environmental cues. The finding may help define the role of cancer stem cells in tumor growth and recurrence.
The study identifies centrosome asymmetry as a key regulator of asymmetric stem cell division, ensuring the correct differential identity of resulting cells. This complex behavior is precisely regulated, coinciding with the orientation in which the stem cell must divide to guarantee asymmetry.
Researchers at Johns Hopkins Medicine identified a core set of 33 microRNAs that regulate adult blood-forming stem cells. These 'master switches' can be targeted to control when stem cells grow into new blood cells, offering potential for new treatments for cancer and bone marrow disorders.
The study reveals that PTEN-deficient intestinal stem cells can lead to changes increasing the number of stem cells and altering their position, resulting in crypt fission and budding. This process can initiate intestinal polyposis and uncontrolled tumor growth.
Researchers found that blood vessels associated with brain tumors create a microenvironment that sustains cancer stem cells. Disrupting this microenvironment with antiangiogenic drugs reduces CSCs and arrests tumor growth.
A study by St. Jude researchers found that brain tumors arise from cancer stem cells living in microscopic protective niches formed by blood vessels, disrupting these niches may block tumor growth. The team showed that targeting blood vessel cells could eliminate CSCs and prevent tumor reappearance following treatment.
A new study has identified a gene that regulates adult stem cell growth, which could lead to increased doses of chemotherapy and faster recovery times for cancer patients. The discovery also opens up possibilities for treating other diseases such as liver disease and diabetes.
A USC study in Nature Genetics finds genes silenced by Polycomb proteins are more likely to be methylated in cancers, supporting a stem cell origin of cancer. The research also shows that epigenetic alterations precede genetic events in cancer development.
Researchers at Cedars-Sinai Medical Center identified genes that make brain cancer-causing stem cells resistant to chemotherapy and other treatments. The study found that these cells can regenerate and become even more aggressive after treatment, highlighting a potential target for new therapies.
Researchers discovered that stem cells communicate with niche cells through the Notch pathway, leading to increased niche cell production and larger stem cell populations. This two-way dialogue enables stem cells to maintain an active niche, which is essential for their self-renewal and differentiation into specialized cells.
Researchers at Duke University Medical Center have found that cancer stem cells in brain tumors activate a 'repair switch' that enables them to continue growing unchecked after radiation treatment. A method to block this process has been identified, offering hope for developing therapies to overcome radiation resistance.
The University of Rochester Medical Center is establishing a leading program in Cancer Stem Cell Research to discover cures for cancer. By studying the 'master cells' of this deadly disease, scientists aim to find underlying causes and develop therapies to target cancer stem cells.
Researchers discovered that breast stem cells lack receptors for female hormones oestrogen and progesterone, resembling the aggressive 'basal' subtype of breast cancer. The findings support speculation that breast stem cells may give rise to basal tumours, which are more common in BRCA1 carriers.
Researchers at Dana-Farber Cancer Institute isolated leukemia stem cells from a mouse model, showing they are surprisingly different from normal blood stem cells. This finding may lead to the development of drugs that selectively target these cells, which could improve treatment outcomes for leukemia patients.
Researchers have grown three-dimensional breast cell cultures to reveal subtleties about stem cells that may explain why they spawn malignancies. The study's findings suggest that these stem cells could become targets for cancer treatment, leading to new therapies that wipe out cancer at its source.
Researchers identified an intrinsic pathway involving PTEN that regulates stem cell transitions between quiescence and activity. Disrupting PTEN leads to increased active cycling and loss of quiescent stem cells, hindering long-term maintenance.
Researchers have discovered that breast stem cells with genetic errors can produce tumours even after chemotherapy. The discovery could lead to the development of new treatments targeting these faulty stem cells.
Columbia University researchers found that stem and progenitor cells are deficient in a quality control checkpoint, leading to chromosomal defects. This deficiency may explain how cancer stem cells arise from normal cells and acquire mutations that increase tumor malignancy.
Researchers identified distinct genetic signatures and cancer stem cell populations driving different subtypes of ependymomas. These findings suggest individualized treatment approaches targeting specific cancer stem cell populations could improve outcomes for patients with these tumors.